Agmatine: Clinical applications after 100 years in translation

John E. Piletz; Feyza Aricioglu; Juei Tang Cheng; Carolyn A. Fairbanks; Varda H. Gilad; Britta Haenisch; Angelos Halaris; Samin Hong; Jong Eun Lee; Jin Li; Ping Liu; Gerhard J. Molderings; Ana Lúcia S. Rodrigues; Joseph Satriano; Gong Je Seong; George Wilcox; Ning Wu; Gad M. Gilad

doi:10.1016/j.drudis.2013.05.017

Agmatine: Clinical applications after 100 years in translation

John E. Piletz, Feyza Aricioglu, Juei Tang Cheng, Carolyn A. Fairbanks, Varda H. Gilad, Britta Haenisch, Angelos Halaris, Samin Hong, Jong Eun Lee, Jin Li, Ping Liu, Gerhard J. Molderings, Ana Lúcia S. Rodrigues, Joseph Satriano, Gong Je Seong, George Wilcox, Ning Wu, Gad M. Gilad

Research output: Contribution to journal › Review article › peer-review

196 Scopus citations

Abstract

Agmatine (decarboxylated arginine) has been known as a natural product for over 100 years, but its biosynthesis in humans was left unexplored owing to long-standing controversy. Only recently has the demonstration of agmatine biosynthesis in mammals revived research, indicating its exceptional modulatory action at multiple molecular targets, including neurotransmitter systems, nitric oxide (NO) synthesis and polyamine metabolism, thus providing bases for broad therapeutic applications. This timely review, a concerted effort by 16 independent research groups, draws attention to the substantial preclinical and initial clinical evidence, and highlights challenges and opportunities, for the use of agmatine in treating a spectrum of complex diseases with unmet therapeutic needs, including diabetes mellitus, neurotrauma and neurodegenerative diseases, opioid addiction, mood disorders, cognitive disorders and cancer.

Original language	English (US)
Pages (from-to)	880-893
Number of pages	14
Journal	Drug Discovery Today
Volume	18
Issue number	17-18
DOIs	https://doi.org/10.1016/j.drudis.2013.05.017
State	Published - Sep 2013

Bibliographical note

Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.drudis.2013.05.017

OpenUrl availability

Full text

Cite this

Piletz, J. E., Aricioglu, F., Cheng, J. T., Fairbanks, C. A., Gilad, V. H., Haenisch, B., Halaris, A., Hong, S., Lee, J. E., Li, J., Liu, P., Molderings, G. J., Rodrigues, A. L. S., Satriano, J., Seong, G. J., Wilcox, G., Wu, N., & Gilad, G. M. (2013). Agmatine: Clinical applications after 100 years in translation. Drug Discovery Today, 18(17-18), 880-893. https://doi.org/10.1016/j.drudis.2013.05.017

Piletz, JE, Aricioglu, F, Cheng, JT, Fairbanks, CA, Gilad, VH, Haenisch, B, Halaris, A, Hong, S, Lee, JE, Li, J, Liu, P, Molderings, GJ, Rodrigues, ALS, Satriano, J, Seong, GJ, Wilcox, G, Wu, N & Gilad, GM 2013, 'Agmatine: Clinical applications after 100 years in translation', Drug Discovery Today, vol. 18, no. 17-18, pp. 880-893. https://doi.org/10.1016/j.drudis.2013.05.017

@article{29e9490167c040aab08aae08348801d1,

title = "Agmatine: Clinical applications after 100 years in translation",

abstract = "Agmatine (decarboxylated arginine) has been known as a natural product for over 100 years, but its biosynthesis in humans was left unexplored owing to long-standing controversy. Only recently has the demonstration of agmatine biosynthesis in mammals revived research, indicating its exceptional modulatory action at multiple molecular targets, including neurotransmitter systems, nitric oxide (NO) synthesis and polyamine metabolism, thus providing bases for broad therapeutic applications. This timely review, a concerted effort by 16 independent research groups, draws attention to the substantial preclinical and initial clinical evidence, and highlights challenges and opportunities, for the use of agmatine in treating a spectrum of complex diseases with unmet therapeutic needs, including diabetes mellitus, neurotrauma and neurodegenerative diseases, opioid addiction, mood disorders, cognitive disorders and cancer.",

author = "Piletz, {John E.} and Feyza Aricioglu and Cheng, {Juei Tang} and Fairbanks, {Carolyn A.} and Gilad, {Varda H.} and Britta Haenisch and Angelos Halaris and Samin Hong and Lee, {Jong Eun} and Jin Li and Ping Liu and Molderings, {Gerhard J.} and Rodrigues, {Ana L{\'u}cia S.} and Joseph Satriano and Seong, {Gong Je} and George Wilcox and Ning Wu and Gilad, {Gad M.}",

year = "2013",

month = sep,

doi = "10.1016/j.drudis.2013.05.017",

language = "English (US)",

volume = "18",

pages = "880--893",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Limited",

number = "17-18",

}

TY - JOUR

T1 - Agmatine

T2 - Clinical applications after 100 years in translation

AU - Piletz, John E.

AU - Aricioglu, Feyza

AU - Cheng, Juei Tang

AU - Fairbanks, Carolyn A.

AU - Gilad, Varda H.

AU - Haenisch, Britta

AU - Halaris, Angelos

AU - Hong, Samin

AU - Lee, Jong Eun

AU - Li, Jin

AU - Liu, Ping

AU - Molderings, Gerhard J.

AU - Rodrigues, Ana Lúcia S.

AU - Satriano, Joseph

AU - Seong, Gong Je

AU - Wilcox, George

AU - Wu, Ning

AU - Gilad, Gad M.

PY - 2013/9

Y1 - 2013/9

N2 - Agmatine (decarboxylated arginine) has been known as a natural product for over 100 years, but its biosynthesis in humans was left unexplored owing to long-standing controversy. Only recently has the demonstration of agmatine biosynthesis in mammals revived research, indicating its exceptional modulatory action at multiple molecular targets, including neurotransmitter systems, nitric oxide (NO) synthesis and polyamine metabolism, thus providing bases for broad therapeutic applications. This timely review, a concerted effort by 16 independent research groups, draws attention to the substantial preclinical and initial clinical evidence, and highlights challenges and opportunities, for the use of agmatine in treating a spectrum of complex diseases with unmet therapeutic needs, including diabetes mellitus, neurotrauma and neurodegenerative diseases, opioid addiction, mood disorders, cognitive disorders and cancer.

AB - Agmatine (decarboxylated arginine) has been known as a natural product for over 100 years, but its biosynthesis in humans was left unexplored owing to long-standing controversy. Only recently has the demonstration of agmatine biosynthesis in mammals revived research, indicating its exceptional modulatory action at multiple molecular targets, including neurotransmitter systems, nitric oxide (NO) synthesis and polyamine metabolism, thus providing bases for broad therapeutic applications. This timely review, a concerted effort by 16 independent research groups, draws attention to the substantial preclinical and initial clinical evidence, and highlights challenges and opportunities, for the use of agmatine in treating a spectrum of complex diseases with unmet therapeutic needs, including diabetes mellitus, neurotrauma and neurodegenerative diseases, opioid addiction, mood disorders, cognitive disorders and cancer.

UR - http://www.scopus.com/inward/record.url?scp=84883250892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883250892&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2013.05.017

DO - 10.1016/j.drudis.2013.05.017

M3 - Review article

C2 - 23769988

AN - SCOPUS:84883250892

SN - 1359-6446

VL - 18

SP - 880

EP - 893

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 17-18

ER -

Agmatine: Clinical applications after 100 years in translation

Abstract

Bibliographical note

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this